DK4028017T3 - 1,4-dihydrobenzo[d]pyrazolo[3,4-f][1,3]diazepinderivater og beslægtede forbindelser som lrrk2-, nuak1- og/eller tyk2- kinasemodulatorer til behandling af for eksempel autoimmune sygdomme - Google Patents

1,4-dihydrobenzo[d]pyrazolo[3,4-f][1,3]diazepinderivater og beslægtede forbindelser som lrrk2-, nuak1- og/eller tyk2- kinasemodulatorer til behandling af for eksempel autoimmune sygdomme Download PDF

Info

Publication number
DK4028017T3
DK4028017T3 DK20788868.6T DK20788868T DK4028017T3 DK 4028017 T3 DK4028017 T3 DK 4028017T3 DK 20788868 T DK20788868 T DK 20788868T DK 4028017 T3 DK4028017 T3 DK 4028017T3
Authority
DK
Denmark
Prior art keywords
nuak1
lrrk2
dihydrobenzo
pyrazolo
treatment
Prior art date
Application number
DK20788868.6T
Other languages
English (en)
Inventor
Roland Koestler
Michael Thormann
Jean Tassel
Nasser Yehia
Andreas Treml
Michael Almstetter
Original Assignee
Origenis Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Origenis Gmbh filed Critical Origenis Gmbh
Application granted granted Critical
Publication of DK4028017T3 publication Critical patent/DK4028017T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
DK20788868.6T 2019-09-13 2020-09-11 1,4-dihydrobenzo[d]pyrazolo[3,4-f][1,3]diazepinderivater og beslægtede forbindelser som lrrk2-, nuak1- og/eller tyk2- kinasemodulatorer til behandling af for eksempel autoimmune sygdomme DK4028017T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962899908P 2019-09-13 2019-09-13
PCT/IB2020/000730 WO2021048620A1 (en) 2019-09-13 2020-09-11 1,4-dihydrobenzo[d]pyrazolo[3,4-f][1,3]diazepine derivatives and related compounds as lrrk2, nuak1 and/or tyk2 kinase modulators for the treatment of e.g. autoimmune disease

Publications (1)

Publication Number Publication Date
DK4028017T3 true DK4028017T3 (da) 2024-01-15

Family

ID=72801756

Family Applications (1)

Application Number Title Priority Date Filing Date
DK20788868.6T DK4028017T3 (da) 2019-09-13 2020-09-11 1,4-dihydrobenzo[d]pyrazolo[3,4-f][1,3]diazepinderivater og beslægtede forbindelser som lrrk2-, nuak1- og/eller tyk2- kinasemodulatorer til behandling af for eksempel autoimmune sygdomme

Country Status (17)

Country Link
US (1) US20220380374A1 (da)
EP (2) EP4028017B1 (da)
JP (1) JP2022548246A (da)
KR (1) KR20220062038A (da)
CN (1) CN114793435B (da)
AU (1) AU2020344216A1 (da)
CA (1) CA3154123A1 (da)
DK (1) DK4028017T3 (da)
ES (1) ES2969088T3 (da)
FI (1) FI4028017T3 (da)
HU (1) HUE065093T2 (da)
IL (1) IL291335A (da)
PL (1) PL4028017T3 (da)
PT (1) PT4028017T (da)
RS (1) RS65045B1 (da)
SI (1) SI4028017T1 (da)
WO (1) WO2021048620A1 (da)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022378463A1 (en) 2021-10-25 2024-05-09 Kymera Therapeutics, Inc. Tyk2 degraders and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101649610B1 (ko) * 2011-04-21 2016-08-19 오리제니스 게엠베하 키나아제 억제제로서의 헤테로사이클릭 화합물

Also Published As

Publication number Publication date
KR20220062038A (ko) 2022-05-13
FI4028017T3 (fi) 2024-01-11
IL291335A (en) 2022-05-01
CN114793435A (zh) 2022-07-26
EP4327884A2 (en) 2024-02-28
AU2020344216A1 (en) 2022-03-31
SI4028017T1 (sl) 2024-04-30
WO2021048620A1 (en) 2021-03-18
JP2022548246A (ja) 2022-11-17
US20220380374A1 (en) 2022-12-01
CA3154123A1 (en) 2021-03-18
PL4028017T3 (pl) 2024-03-18
EP4327884A3 (en) 2024-05-01
HUE065093T2 (hu) 2024-05-28
EP4028017A1 (en) 2022-07-20
PT4028017T (pt) 2024-01-16
CN114793435B (zh) 2024-10-01
EP4028017B1 (en) 2023-12-06
RS65045B1 (sr) 2024-02-29
ES2969088T3 (es) 2024-05-16

Similar Documents

Publication Publication Date Title
DK3658539T3 (da) Forbindelser og sammensætninger til behandling af tilstande, som er forbundet med nlrp-aktivitet
DK3752510T3 (da) Makrocyklusser som modulatorer af cystisk fibrose transmembrankonduktansregulator, farmaceutiske sammensætninger deraf, deres anvendelse i behandlingen af cystisk fibrose og fremgangsmåde til fremstilling deraf
IL291338A (en) 1,4-dihydrobenzo[d]pyrazolo[f-3,4]diazepine derivatives and related compounds as modulators of lrrk2, nuak1 and/or tyk2 kinase for the treatment of diseases such as autoimmune diseases
DK3938047T3 (da) Broforbundne tricykliske carbamoylpyridonforbindelser og deres farmaceutiske anvendelse
CL2016002836A1 (es) Compuestos derivados de pirido pirimidin con actividad moduladora del empalme genico de smn2; composicion farmaceutica y uso en el tratamiento de la atrofia muscular espinal (ame).
DK3737684T3 (da) 2,4,6,7-tetrahydro-pyrazolo[4,3-d]pyrimidin-5-on-derivater og relaterede forbindelser som c5a-receptormodulatorer til behandling af vaskulitis og inflammatoriske sygdomme
SG11202107978RA (en) Methods and system for the reconstruction of drug response and disease networks and uses thereof
DK3681500T3 (da) Anvendelse af pilocarpinhydrochlorid til behandling af presbyopi
UY38338A (es) INHIBIDORES DE LA INTERACCIÓN PROTEÍNA-PROTEÍNA KEAP1-Nrf2
NZ736055A (en) Imidazopyrazines and pyrazolopyrimidines and their use as ampa receptor modulators
DK3801909T3 (da) Kornmølle og valsestol med flere malepassager til optimeret maling af produkter samt tilsvarende fremgangsmåde
DK3524609T3 (da) Fremgangsmåde til fremstilling af 3-phenyl-2,3,4,8,9,10-hexahydropyrano[2,3-f]chromenderivater, optiske isomerer deraf og mellemprodukter fra processen
DOP2017000087A (es) Moduladores de pirrolopiridina de rorc2 sustituidos con metilo y trifluorometilo y métodos de uso de los mismos
DK3509598T3 (da) Ny anvendelse af triazolo(4,5-d)pyrimidinderivater til forebyggelse og behandling af bakteriel infektion
DK4003998T3 (da) N-methyl, n-(6-(methoxy)pyridazin-3-yl) aminderivater som au-totaxin (atx) modulatorer til behandlingen af inflammatorisk luftvejs- eller fibrotiske sygdomme
DK4028017T3 (da) 1,4-dihydrobenzo[d]pyrazolo[3,4-f][1,3]diazepinderivater og beslægtede forbindelser som lrrk2-, nuak1- og/eller tyk2- kinasemodulatorer til behandling af for eksempel autoimmune sygdomme
DK4003978T3 (da) N-methyl, n-(6-(methoxy)pyridazin-3-yl) aminderivater som autotaxin (atx) modulatorer til behandlingen af inflammatoriske luftvejs- eller fibrotiske sygdomme
DK3573948T3 (da) Fremgangsmåder til fremstilling af cytotoksiske benzodiazepinderivater
EP3750537A4 (en) PHARMACEUTICAL COMPOSITION, EXCIPIENT FOR THE COMPOSITION AND USE OF THE COMPOSITION
DK4036095T3 (da) 4-fluor-1h-pyrazolo[3,4-c]pyridinderivater som selektive bruton-tyrosinkinase- (btk) inhibitorer til behandlingen af b-cellelymfom og autoimmunsygdomme
DK4031117T3 (da) NGF-mutant til anvendelse i behandling eller forebyggelse af oftalmiske lidelser
DK3829579T3 (da) 1,3,8-triazaspiro-forbindelser og anvendelse deraf som lægemidler til behandling af reperfusionsskader
MX2021004471A (es) Derivados de pirrolo-pididazina como moduladores alostéricos positivos del receptor muscarínico m1.
DK3914258T3 (da) Sammensætning til behandling af periodontitis og regeneration af interdental papi
DK3634957T3 (da) Nmda-receptormodulatorer, sammensætninger, der omfatter samme, og anvendelse af disse forbindelser i behandlingen af sygdomme, der omfatter centralnervesystemet